Ryutaro Kikuchi
Papers
1
Total Citations
6
H-Index
1
About
Dr. Ryutaro Kikuchi is a leading thoracic surgeon and researcher whose work focuses on the intersection of immunotherapy and surgical oncology for non-small cell lung cancer (NSCLC). His major contribution lies in pioneering the concept of salvage surgery following immune checkpoint inhibitor (ICI) therapy for initially unresectable NSCLC—a paradigm-shifting approach that bridges advanced medical oncology with curative-intent surgery. His landmark 2024 study, cited 6 times, was the first to systematically characterize outcomes of patients who underwent resection after ICI treatment, demonstrating that salvage surgery is both feasible and potentially life-extending for this previously inoperable population. This work has opened new therapeutic avenues for patients with advanced lung cancer, challenging traditional treatment boundaries. Dr. Kikuchi’s research continues to shape how thoracic surgeons and oncologists integrate immunotherapy with surgical strategies, offering renewed hope for patients with initially unresectable disease. His ongoing investigations into perioperative outcomes and long-term survival are poised to further refine this emerging clinical pathway.
Research Focus
Key Achievements
Top Papers
- 1